NCT05115669 is a NA clinical trial of Wortie freeze plus in Common Wart, sponsored by Karo Pharma AB.

Who is sponsoring NCT05115669?

NCT05115669 is sponsored by Karo Pharma AB.

What drugs are being tested in NCT05115669?

Interventions in NCT05115669: Wortie freeze plus.

What condition does NCT05115669 study?

NCT05115669 studies Common Wart, Plantar Wart.

Is NCT05115669 still recruiting?

NCT05115669 is currently completed. Last updated 21 February 2023.

Last reviewed 2023-02-21 · How we verify

NCT05115669

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts

Completed NA Last updated 21 February 2023

What this trial tests

NA trial testing Wortie freeze plus in Common Wart in 50 participants. Completed in 1 May 2022.

Timeline

12 October 2021

Primary endpoint
1 May 2022

1 May 2022

Quick facts

Lead sponsor	Karo Pharma AB
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	12 October 2021
Primary completion	1 May 2022
Estimated completion	1 May 2022
Sites	1 location across Poland

Drugs / interventions tested

Wortie freeze plus

Conditions studied

Common Wart — all drugs for Common Wart →
Plantar Wart — all drugs for Plantar Wart →

Sponsor

Karo Pharma AB

Who can join

12 and older, any sex, with Common Wart or Plantar Wart. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Post-Market clinical Follow-up investigation to evaluate the safety and performed of the medical device Wortie Freeze Plus in the treatment of common and plantar warts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Common Wart

Currently open trials in the same condition.

NCT07448844 — Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir · Phase 4 · recruiting
NCT03977753 — Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatmen · Phase 4 · recruiting

Other Karo Pharma AB trials

Trials by the same sponsor.

NCT07233473 — Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections · NA · recruiting
NCT07234786 — Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections · NA · recruiting
NCT05552378 — Multi-Gyn FloraFem Study for Treatment of Vulvo Vaginal Candidiasis Symptoms · NA · completed
NCT05732337 — Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device. · NA · completed
NCT05560841 — Effectiveness and Safety of Nailner Brush 2in1 in Onychomycosis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05115669 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karo Pharma AB
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05115669.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing